This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Urges Innovators to produce quality products that can be deployed at scale
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
UTD2 is the world's first oral epothilone microtubule inhibitor
Pfizer is likely to show GSK significant competition
Subscribe To Our Newsletter & Stay Updated
